Targeted therapy with immunotherapy for lung cancer or melanoma
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of two drugs, larotrectinib and pembrolizumab, for people with advanced lung adenocarcinoma or melanoma that has grown after previous immunotherapy. The drugs aim to help the immune system fight the cancer more effectively.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have advanced lung adenocarcinoma or melanoma that has grown after at least one dose of immunotherapy.
- You must be willing to have a tumor biopsy if it is safe and feasible.
- You must be able to take pills by mouth.
- You must have adequate organ function, which will be checked by blood tests.
- You must agree to use effective birth control during and for 4 months after treatment.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new approach: taking immune cells from your own tumor (TILs), growing them in the lab, then giving them back to you along with the immunotherapy drug pembrolizumab. It is for people with advanced lung cancer who have run out of standard options.
This trial tests two drugs, benmelstobart (immunotherapy) and anlotinib (a targeted therapy), alone or combined, before surgery for non-small cell lung cancer. The goal is to see if these drugs shrink the tumor enough to improve the chances of a complete response after surgery.
This trial tests a new drug, ILKN421H, combined with pembrolizumab (a type of immunotherapy) for people with advanced non-small cell lung cancer (NSCLC) that has not responded to standard treatments or has not been treated before. It aims to see if this combination can help shrink tumors or slow their growth.
This trial tests combining two drugs—pembrolizumab (an immunotherapy that helps your immune system fight cancer) and irinotecan (a chemotherapy drug)—for people with advanced melanoma. It aims to see if this combination is safe and effective for those who have not yet been treated for metastatic disease.
This trial tests a combination of medicines given before surgery and immunotherapy after surgery for resectable non-small cell lung cancer (NSCLC). It aims to shrink the tumor before the operation and reduce the risk of cancer coming back after surgery.
This trial tests a new combination of two drugs (Adibelimab and Famitinib) plus chemotherapy for people with advanced non-small cell lung cancer whose previous immunotherapy (PD-1 inhibitor) has stopped working. The goal is to see if this new combination can help control the cancer when the first treatment fails.
Hear when a new Solid Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.